Coronary Artery Calcification, Dyslipidemias, Metabolic Syndrome
Conditions
Brief summary
The aim of this study is to compare safety and efficacy between the aggressive treatment with combination of high-intensity statin and ezetimibe and the current standard lipid lowering treatment in asymptomatic patients with presence of coronary calcification.
Detailed description
Atherosclerotic cardiovascular diseases (ASCVD), such as myocardial infarction (MI), ischemic stroke, or peripheral arterial disease, are the leading cause of morbidity and mortality worldwide. The causality of low-density lipoproteins cholesterol (LDL-C) level in the development of ASCVD is well demonstrated in previous studies. After introducing LDL-C lowering agents, multiple large-scale randomized clinical trials have demonstrated lower cardiovascular events with lowering LDL-C levels. In particular, for secondary prevention, more aggressive control of LDL-C levels with high-intensity statin therapy significantly reduced cardiovascular events compared with moderate-intensity statin therapy. In addition, the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) proved the clinical efficacy of additive ezetimibe for incrementally lowering of LDL-C levels in patients with acute coronary syndrome. However, there has been limited evidence regarding the efficacy and safety of aggressive lipid-lowering strategy using high-intensity statin with a combination of ezetimibe for primary prevention of cardiovascular events among persons without cardiovascular disease. Although the Heart Outcomes Prevention Evaluation (HOPE)-3 and Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trials consistently identified that the use of rosuvastatin (10 mg or 20 mg) was significantly associated with reduced future risk of major cardiovascular events in patients who did not have cardiovascular disease, those studies have been focused on the use of statin, not on the intensity of statin. The coronary artery calcium (CAC) scan, a marker of subclinical coronary atherosclerosis, has become popular for individuals at risk for atherosclerotic cardiovascular disease. CAC is strongly associated with atherosclerotic burden and predicts coronary heart disease events and mortality, regardless of their age, sex, race, or ASCVD risk. Furthermore, the progression of CAC is associated with an increased risk for future hard and total coronary heart disease events. The use of CAC scoring was associated with significant improvements in the reclassification and discrimination of incident ASCVD. Nevertheless, the current guidelines recommend CAC measurement for selected cases only with borderline or intermediate risk of ASCVD to guide the use of statin or not. However, in real-world practice, CAC testing is increasingly being promoted to the public as a means of self-assessment of cardiovascular risk and is widely being used regardless of ASCVD risk. Considering that statin has additional properties, including atherosclerotic plaque stabilization, oxidative stress reduction, enhancement of endothelial function, and a decrease in vascular inflammation beyond their lipid-lowering effect, aggressive treatment with a high-intensity statin plus ezetimibe combination might have beneficial effects on the long-term clinical outcomes for asymptomatic patients with significant coronary calcium (Agatston Score ≥ 100) compared with standard lipid-lowering therapy endorsed by the current guidelines. Therefore, the purpose of DECISION-CALCIUM (Comparison of Efficacy and Safety of High-Intensity Statin and Ezetimibe Combination versus StanDard carE in AsymptomatiC PatIentS wIth Presence of COroNary Artery CALCIUM) trial is to compare the efficacy and safety of the aggressive lipid-lowering therapy with combination of high-intensity statin and ezetimibe, compared with the current standard lipid-lowering therapy in asymptomatic patients with significant coronary calcification for primary prevention.
Interventions
DRUGGuideline directed statin therapy
At least moderate intensity statin, recommended by the current guideline based on the ASCVD risk
DRUGHigh intensity statin plus ezetimibe therapy
Rosuvastatin 20 mg + Ezetimibe 10 mg
Sponsors
Samsung Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
A prospective, open label, multicenter randomized controlled trial
Intervention model description
standard treatment vs. aggressive treatment
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject must be at least 40 years of age. * Asymptomatic patients with presence of coronary calcification (Agatston Score ≥ 100) * low-density lipoproteins cholesterol (LDL-C) \<190 mg/dL
Exclusion criteria
* Objective evidence of at least moderate inducible ischemia requiring revascularization treatment * History of cerebrovascular disease * History of coronary or peripheral arterial revascularization * Active liver disease or persistent unexplained serum transaminase elevations more than 2 times the upper limit of normal range * History of any adverse drug reaction requiring discontinuation of statin (e, g. rhabdomyolysis) * Allergy or sensitivity to any statin or ezetimibe * Concurrent treatment with cyclosporine or a condition likely to result in organ transplantation and the need for cyclosporine * Pregnancy or breast feeding * Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment) * Unwillingness or inability to comply with the procedures described in this protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major adverse cardiovascular events | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | a composite of death from any causes, myocardial infarction, stroke, unplanned coronary revascularization, or other arterial revascularization procedure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiovascular death | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | Death from cardiovascular causes |
| Stroke | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | Ischemic or hemorrhagic stroke |
| Unplanned coronary revascularization | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | revascularization procedure to coronary artery |
| Arterial revascularization procedure | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | All arterial revascularization procedure |
| Major bleeding | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | Bleeding Academic Research Consortium (BARC) type 3-5 |
| Bleeding | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | BARC type 2-5 |
| Heart failure hospitalization | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | Hospitalization due to heart failure |
| All-cause death | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | Death from any causes |
| Changes of LDL-C | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | Delta LDL-C |
| New-onset diabetes mellitus | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | Occurence of new-onset diabetes mellitus |
| Hepatic disorder requiring discontinuation of statin | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | Occurence of hepatic disorder requiring discontinuation of statin |
| muscle-related adverse events | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | Occurence of muscle-related adverse events due to statin |
| Proportion of patients with LDL-C < 100mg/dL | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | Proportion of patients with LDL-C \< 100mg/dL |
| Proportion of patients with LDL-C < 70mg/dL | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | Proportion of patients with LDL-C \< 70mg/dL |
| Coronary calcium progression | up to 4.5 years of median follow-up (till 3 year after the last patient enrollment) | Delta CAC |
Countries
South Korea
Contacts
Primary ContactSeung-Hyuk Choi, MD
Backup ContactKi Hong Choi, MD
Outcome results
None listed